Intrinsic value of Paratek Pharmaceuticals - PRTK

Previous Close

$6.85

  Intrinsic Value

$0.65

stock screener

  Rating & Target

str. sell

-91%

Previous close

$6.85

 
Intrinsic value

$0.65

 
Up/down potential

-91%

 
Rating

str. sell

We calculate the intrinsic value of PRTK stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  13
  13
  14
  14
  14
  15
  15
  16
  16
  17
  18
  18
  19
  20
  21
  22
  23
  24
  25
  26
  27
  28
  30
  31
  33
  34
  36
  38
  39
  41
Variable operating expenses, $m
  48,749
  49,870
  51,152
  52,591
  54,185
  55,935
  57,840
  59,902
  62,123
  64,507
  67,058
  69,779
  72,677
  75,757
  79,025
  82,488
  86,154
  90,030
  94,127
  98,451
  103,015
  107,827
  112,900
  118,245
  123,874
  129,801
  136,040
  142,604
  149,511
  156,775
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  48,749
  49,870
  51,152
  52,591
  54,185
  55,935
  57,840
  59,902
  62,123
  64,507
  67,058
  69,779
  72,677
  75,757
  79,025
  82,488
  86,154
  90,030
  94,127
  98,451
  103,015
  107,827
  112,900
  118,245
  123,874
  129,801
  136,040
  142,604
  149,511
  156,775
Operating income, $m
  -48,736
  -49,857
  -51,139
  -52,577
  -54,171
  -55,920
  -57,824
  -59,886
  -62,107
  -64,490
  -67,040
  -69,761
  -72,658
  -75,737
  -79,004
  -82,466
  -86,131
  -90,007
  -94,102
  -98,425
  -102,988
  -107,799
  -112,870
  -118,214
  -123,842
  -129,767
  -136,004
  -142,567
  -149,471
  -156,734
EBITDA, $m
  -48,736
  -49,857
  -51,138
  -52,577
  -54,170
  -55,919
  -57,824
  -59,885
  -62,106
  -64,490
  -67,040
  -69,760
  -72,657
  -75,736
  -79,003
  -82,465
  -86,130
  -90,006
  -94,101
  -98,425
  -102,987
  -107,798
  -112,869
  -118,213
  -123,841
  -129,766
  -136,003
  -142,566
  -149,470
  -156,732
Interest expense (income), $m
  2
  6
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  4
  4
  4
  5
  5
  5
  6
Earnings before tax, $m
  -48,742
  -49,858
  -51,139
  -52,578
  -54,172
  -55,921
  -57,825
  -59,887
  -62,108
  -64,491
  -67,041
  -69,762
  -72,659
  -75,738
  -79,006
  -82,468
  -86,133
  -90,009
  -94,104
  -98,428
  -102,991
  -107,802
  -112,874
  -118,218
  -123,846
  -129,771
  -136,009
  -142,572
  -149,477
  -156,739
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -48,742
  -49,858
  -51,139
  -52,578
  -54,172
  -55,921
  -57,825
  -59,887
  -62,108
  -64,491
  -67,041
  -69,762
  -72,659
  -75,738
  -79,006
  -82,468
  -86,133
  -90,009
  -94,104
  -98,428
  -102,991
  -107,802
  -112,874
  -118,218
  -123,846
  -129,771
  -136,009
  -142,572
  -149,477
  -156,739

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  28
  29
  29
  30
  31
  32
  33
  34
  36
  37
  39
  40
  42
  44
  45
  47
  50
  52
  54
  57
  59
  62
  65
  68
  71
  75
  78
  82
  86
  90
Adjusted assets (=assets-cash), $m
  28
  29
  29
  30
  31
  32
  33
  34
  36
  37
  39
  40
  42
  44
  45
  47
  50
  52
  54
  57
  59
  62
  65
  68
  71
  75
  78
  82
  86
  90
Revenue / Adjusted assets
  0.464
  0.448
  0.483
  0.467
  0.452
  0.469
  0.455
  0.471
  0.444
  0.459
  0.462
  0.450
  0.452
  0.455
  0.467
  0.468
  0.460
  0.462
  0.463
  0.456
  0.458
  0.452
  0.462
  0.456
  0.465
  0.453
  0.462
  0.463
  0.453
  0.456
Average production assets, $m
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  6
  6
  6
  7
  7
Working capital, $m
  -8
  -9
  -9
  -9
  -9
  -10
  -10
  -10
  -11
  -11
  -11
  -12
  -12
  -13
  -14
  -14
  -15
  -15
  -16
  -17
  -18
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -26
  -27
Total debt, $m
  3
  4
  4
  5
  6
  7
  8
  9
  10
  11
  13
  14
  16
  17
  19
  21
  23
  25
  27
  29
  31
  34
  36
  39
  42
  45
  48
  52
  55
  59
Total liabilities, $m
  25
  26
  26
  27
  28
  29
  30
  31
  32
  33
  35
  36
  38
  39
  41
  43
  45
  47
  49
  51
  53
  56
  58
  61
  64
  67
  70
  74
  77
  81
Total equity, $m
  3
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
  8
  8
  9
  9
Total liabilities and equity, $m
  28
  29
  29
  30
  31
  32
  33
  34
  36
  37
  39
  40
  42
  43
  46
  48
  50
  52
  54
  57
  59
  62
  64
  68
  71
  74
  78
  82
  86
  90
Debt-to-equity ratio
  1.140
  1.320
  1.510
  1.710
  1.930
  2.150
  2.380
  2.600
  2.830
  3.060
  3.290
  3.510
  3.730
  3.940
  4.150
  4.360
  4.550
  4.740
  4.930
  5.110
  5.280
  5.450
  5.610
  5.760
  5.910
  6.050
  6.180
  6.310
  6.440
  6.560
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -48,742
  -49,858
  -51,139
  -52,578
  -54,172
  -55,921
  -57,825
  -59,887
  -62,108
  -64,491
  -67,041
  -69,762
  -72,659
  -75,738
  -79,006
  -82,468
  -86,133
  -90,009
  -94,104
  -98,428
  -102,991
  -107,802
  -112,874
  -118,218
  -123,846
  -129,771
  -136,009
  -142,572
  -149,477
  -156,739
Depreciation, amort., depletion, $m
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
Funds from operations, $m
  -48,742
  -49,857
  -51,138
  -52,577
  -54,171
  -55,920
  -57,825
  -59,886
  -62,107
  -64,491
  -67,041
  -69,762
  -72,659
  -75,738
  -79,005
  -82,467
  -86,132
  -90,008
  -94,103
  -98,427
  -102,990
  -107,801
  -112,873
  -118,217
  -123,845
  -129,770
  -136,007
  -142,571
  -149,475
  -156,738
Change in working capital, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
Cash from operations, $m
  -48,742
  -49,857
  -51,138
  -52,577
  -54,171
  -55,920
  -57,824
  -59,886
  -62,107
  -64,490
  -67,040
  -69,761
  -72,658
  -75,737
  -79,004
  -82,467
  -86,132
  -90,007
  -94,103
  -98,427
  -102,989
  -107,800
  -112,872
  -118,216
  -123,844
  -129,769
  -136,006
  -142,569
  -149,474
  -156,737
Maintenance CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
New CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from investing activities, $m
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
Free cash flow, $m
  -48,742
  -49,857
  -51,139
  -52,577
  -54,171
  -55,920
  -57,825
  -59,886
  -62,107
  -64,491
  -67,041
  -69,762
  -72,659
  -75,738
  -79,005
  -82,468
  -86,133
  -90,008
  -94,104
  -98,428
  -102,990
  -107,802
  -112,873
  -118,217
  -123,845
  -129,771
  -136,008
  -142,571
  -149,476
  -156,738
Issuance/(repayment) of debt, $m
  -56
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  4
  4
Issuance/(repurchase) of shares, $m
  48,798
  49,858
  51,139
  52,578
  54,172
  55,921
  57,825
  59,887
  62,108
  64,492
  67,041
  69,763
  72,660
  75,739
  79,006
  82,468
  86,133
  90,009
  94,104
  98,428
  102,991
  107,802
  112,874
  118,218
  123,846
  129,772
  136,009
  142,572
  149,477
  156,740
Cash from financing (excl. dividends), $m  
  48,742
  49,859
  51,140
  52,579
  54,173
  55,922
  57,826
  59,888
  62,109
  64,493
  67,042
  69,764
  72,661
  75,741
  79,008
  82,470
  86,135
  90,011
  94,106
  98,430
  102,993
  107,804
  112,877
  118,221
  123,849
  129,775
  136,012
  142,575
  149,481
  156,744
Total cash flow (excl. dividends), $m
  -0
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  5
  5
  5
Retained Cash Flow (-), $m
  -48,798
  -49,858
  -51,139
  -52,578
  -54,172
  -55,921
  -57,825
  -59,887
  -62,108
  -64,492
  -67,041
  -69,763
  -72,660
  -75,739
  -79,006
  -82,468
  -86,133
  -90,009
  -94,104
  -98,428
  -102,991
  -107,802
  -112,874
  -118,218
  -123,846
  -129,772
  -136,009
  -142,572
  -149,477
  -156,740
Prev. year cash balance distribution, $m
  135
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -48,663
  -49,857
  -51,138
  -52,576
  -54,170
  -55,919
  -57,824
  -59,885
  -62,106
  -64,490
  -67,040
  -69,761
  -72,658
  -75,736
  -79,004
  -82,466
  -86,131
  -90,006
  -94,102
  -98,425
  -102,988
  -107,799
  -112,871
  -118,214
  -123,842
  -129,768
  -136,004
  -142,568
  -149,472
  -156,735
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -46,657
  -45,642
  -44,504
  -43,291
  -41,989
  -40,583
  -39,065
  -37,430
  -35,677
  -33,809
  -31,836
  -29,769
  -27,626
  -25,426
  -23,194
  -20,956
  -18,741
  -16,576
  -14,489
  -12,507
  -10,652
  -8,944
  -7,398
  -6,021
  -4,818
  -3,786
  -2,919
  -2,206
  -1,632
  -1,180
Current shareholders' claim on cash, %
  50.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.

FINANCIAL RATIOS  of  Paratek Pharmaceuticals (PRTK)

Valuation Ratios
P/E Ratio -1.4
Price to Sales 0
Price to Book 2.2
Price to Tangible Book
Price to Cash Flow -1.7
Price to Free Cash Flow -1.7
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0.1
LT Debt to Equity 55.6%
Total Debt to Equity 55.6%
Interest Coverage -55
Management Effectiveness
Return On Assets -78%
Ret/ On Assets - 3 Yr. Avg. -55.3%
Return On Total Capital -95.7%
Ret/ On T. Cap. - 3 Yr. Avg. -71.4%
Return On Equity -129.5%
Return On Equity - 3 Yr. Avg. -87%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. -150%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. -66.7%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. -150%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. -150%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

PRTK stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the PRTK stock intrinsic value calculation we used $12.616 million for the last fiscal year's total revenue generated by Paratek Pharmaceuticals. The default revenue input number comes from 0001 income statement of Paratek Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our PRTK stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for PRTK is calculated based on our internal credit rating of Paratek Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Paratek Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of PRTK stock the variable cost ratio is equal to 378830.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for PRTK stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 10.3% for Paratek Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for Paratek Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the PRTK stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for PRTK are equal to 16.6%.

Life of production assets of 2.3 years is the average useful life of capital assets used in Paratek Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for PRTK is equal to -64.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $82.478 million for Paratek Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 31.596 million for Paratek Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Paratek Pharmaceuticals at the current share price and the inputted number of shares is $0.2 billion.

RELATED COMPANIES Price Int.Val. Rating
TTPH Tetraphase Pha 2.05 0.63  str.sell
NBRV Nabriva Therap 2.04 0.42  str.sell
MRK Merck&Co 74.61 33.05  str.sell
JNJ Johnson&Johnso 144.68 176.79  buy
PFE Pfizer 43.52 34.10  hold

COMPANY NEWS

▶ Paratek: 3Q Earnings Snapshot   [04:48PM  Associated Press]
▶ War against the superbugs: Mass. biotechs step up to fight antibiotic resistance   [Oct-25-18 01:12PM  American City Business Journals]
▶ Major Action in Biotech and This is The Next Winner   [Oct-05-18 10:55AM  ACCESSWIRE]
▶ Paratek gets second FDA approval in past 24 hours   [12:43PM  American City Business Journals]
▶ US regulators OK updated version of decades-old antibiotic   [Oct-02-18 07:18PM  Associated Press]
▶ Mass. antibiotics developers say the field is getting slowly better   [Aug-30-18 06:21AM  American City Business Journals]
▶ FDA panel recommends approval of Paratek's antibiotic   [Aug-08-18 04:07PM  American City Business Journals]
▶ Paratek: 2Q Earnings Snapshot   [05:58PM  Associated Press]
▶ Paratek: 1Q Earnings Snapshot   [May-09-18 08:01AM  Associated Press]
▶ Heres Whats Moving Conatus And Paratek   [08:32AM  Market Exclusive]
▶ Top Growth Stocks To Buy Today   [Feb-14-18 11:02AM  Simply Wall St.]
▶ Why Paratek Pharmaceuticals Is Sinking Today   [Jan-18-18 04:09PM  Motley Fool]
▶ Paratek Announces Public Offering of Common Stock   [Jan-17-18 04:06PM  GlobeNewswire]
▶ Paratek Provides Update on Pipeline Progress   [Jan-03-18 07:00AM  GlobeNewswire]
▶ Best-In-Class NasdaqGM Growth Stocks   [Dec-10-17 11:02AM  Simply Wall St.]
▶ 3 Companies Spearheading the Antibiotics Space in 2018   [Nov-10-17 11:15AM  24/7 Wall St.]
▶ Paratek reports 3Q loss   [08:15AM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.